There are 702 resources available
164TiP - Cytoreductive surgery and HIPEC using double agent (cisplatin+mitomycin-C) in patients with colorectal cancer: A prospective randomized controlled study
Presenter: Manindra Nayak
Session: Poster Display session
166P - Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unrese
Presenter: Stephen Chan
Session: Poster Display session
167P - Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Maria Elisa Reig Monzon
Session: Poster Display session
168P - Characterization of tumor response with lenvatinib (LEN) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT
Presenter: Arndt Vogel
Session: Poster Display session
169P - Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Presenter: Lorenza Rimassa
Session: Poster Display session
170P - Efficacy of the combination of transarterial chemoembolization (TACE) and immunotherapy of atezolizumab + bevacizumab in patients before liver resection and transplantation (OTP) with hepatocellular carcinoma (HCC)
Presenter: Kate Nasonova
Session: Poster Display session
171P - A phase II study of ABSK-011 plus atezolizumab in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Xiao-Ping Chen
Session: Poster Display session
172P - TACE combined with tislelizumab and TKI as a conversion therapy in initial unresectable hepatocellular carcinoma (uHCC): A prospective single-arm phase II clinical study
Presenter: Shaoping Liu
Session: Poster Display session
173P - A phase II trial of donafenib plus sintilimab for advanced stage hepatocellular carcinoma
Presenter: Mingyue Cai
Session: Poster Display session
174P - A single-arm open-label pilot study of combination therapy of TACE in combination with ablation and durvalumab in unresectable hepatocellular carcinoma patients (TAD study)
Presenter: Bei Tang
Session: Poster Display session